These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 32926241)
1. Should We Use Genetic Scores in the Determination of Treatment Strategies to Control Dyslipidemias? Lechner K; Kessler T; Schunkert H Curr Cardiol Rep; 2020 Sep; 22(11):146. PubMed ID: 32926241 [TBL] [Abstract][Full Text] [Related]
2. How Do We Incorporate Polygenic Risk Scores in Cardiovascular Disease Risk Assessment and Management? Hadley TD; Agha AM; Ballantyne CM Curr Atheroscler Rep; 2021 Apr; 23(6):28. PubMed ID: 33791884 [TBL] [Abstract][Full Text] [Related]
3. Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options. Berman AN; Blankstein R Curr Cardiol Rep; 2019 Aug; 21(9):110. PubMed ID: 31378838 [TBL] [Abstract][Full Text] [Related]
4. Risk Categorization Using New American College of Cardiology/American Heart Association Guidelines for Cholesterol Management and Its Relation to Alirocumab Treatment Following Acute Coronary Syndromes. Roe MT; Li QH; Bhatt DL; Bittner VA; Diaz R; Goodman SG; Harrington RA; Jukema JW; Lopez-Jaramillo P; Lopes RD; Louie MJ; Moriarty PM; Szarek M; Vogel R; White HD; Zeiher AM; Baccara-Dinet MT; Steg PG; Schwartz GG Circulation; 2019 Nov; 140(19):1578-1589. PubMed ID: 31475572 [TBL] [Abstract][Full Text] [Related]
15. Statin therapy for young adults: A long-term investment worth considering. Miedema MD; Nauffal VD; Singh A; Blankstein R Trends Cardiovasc Med; 2020 Jan; 30(1):48-53. PubMed ID: 30808553 [TBL] [Abstract][Full Text] [Related]
16. Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. Damask A; Steg PG; Schwartz GG; Szarek M; Hagström E; Badimon L; Chapman MJ; Boileau C; Tsimikas S; Ginsberg HN; Banerjee P; Manvelian G; Pordy R; Hess S; Overton JD; Lotta LA; Yancopoulos GD; Abecasis GR; Baras A; Paulding C; Circulation; 2020 Feb; 141(8):624-636. PubMed ID: 31707832 [TBL] [Abstract][Full Text] [Related]
17. Inflammation and Cardiovascular Disease: The Future. Arnold N; Lechner K; Waldeyer C; Shapiro MD; Koenig W Eur Cardiol; 2021 Feb; 16():e20. PubMed ID: 34093741 [TBL] [Abstract][Full Text] [Related]
18. Trajectories of Blood Lipid Concentrations Over the Adult Life Course and Risk of Cardiovascular Disease and All-Cause Mortality: Observations From the Framingham Study Over 35 Years. Duncan MS; Vasan RS; Xanthakis V J Am Heart Assoc; 2019 Jun; 8(11):e011433. PubMed ID: 31137992 [TBL] [Abstract][Full Text] [Related]
19. Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease. Chan J; Rajalingam T; Fossella J; Zhou H; Eisenberg N; Roche-Nagle G Ann Vasc Surg; 2020 Nov; 69():197-205. PubMed ID: 32554202 [TBL] [Abstract][Full Text] [Related]
20. [Essence of the Japan Atherosclerosis Society (JAS) Guidelines for the Diagnosis and Prevention of Atherosclerotic Cardiovascular Diseases in Japan-2012 Version and Treatment Guide for Dyslipidemia 2013--Current Strategy for the Lipid Assessment]. Arai H Rinsho Byori; 2014 Sep; 62(9):878-83. PubMed ID: 27526533 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]